Literature DB >> 32220891

Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer.

Philip W Kantoff1,2, Wassim Abida1,2, Konrad H Stopsack3, Subhiksha Nandakumar4,5,6, Andreas G Wibmer7, Samuel Haywood8, Emily S Weg9, Ethan S Barnett3, Chloe J Kim3, Emily A Carbone3, Samantha E Vasselman3, Bastien Nguyen4,5,6, Melanie A Hullings3, Howard I Scher3,2, Michael J Morris3,2, David B Solit3,4,5,2, Nikolaus Schultz4,5,6.   

Abstract

PURPOSE: The genomic underpinning of clinical phenotypes and outcomes in metastatic castration-sensitive prostate cancer is unclear. EXPERIMENTAL
DESIGN: In patients with metastatic castration-sensitive prostate cancer at a tertiary referral center, clinical-grade targeted tumor sequencing was performed to quantify tumor DNA copy number alterations and alterations in predefined oncogenic signaling pathways. Disease volume was classified as high volume (≥4 bone metastases or visceral metastases) versus low volume.
RESULTS: Among 424 patients (88% white), 213 (50%) had high-volume disease and 211 (50%) had low-volume disease, 275 (65%) had de novo metastatic disease, and 149 (35%) had metastatic recurrence of nonmetastatic disease. Rates of castration resistance [adjusted hazard ratio, 1.84; 95% confidence interval (CI), 1.40-2.41] and death (adjusted hazard ratio, 3.71; 95% CI, 2.28-6.02) were higher in high-volume disease. Tumors from high-volume disease had more copy number alterations. The NOTCH, cell cycle, and epigenetic modifier pathways were the highest-ranking pathways enriched in high-volume disease. De novo metastatic disease differed from metastatic recurrences in the prevalence of CDK12 alterations but had similar prognosis. Rates of castration resistance differed 1.5-fold to 5-fold according to alterations in AR, SPOP (inverse), and TP53, and the cell cycle, WNT (inverse), and MYC pathways, adjusting for disease volume and other genomic pathways. Overall survival rates differed 2-fold to 4-fold according to AR, SPOP (inverse), WNT (inverse), and cell-cycle alterations. PI3K pathway alterations were not associated with prognosis once adjusted for other factors.
CONCLUSIONS: This study identified genomic features associated with prognosis in metastatic castration-sensitive disease that may aid in molecular classification and treatment selection. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID： 32220891      PMCID： PMC7334067          DOI： 10.1158/1078-0432.CCR-20-0168

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  42 in total

1.  Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.

Authors:  Clarissa Gerhauser; Francesco Favero; Thomas Risch; Ronald Simon; Lars Feuerbach; Yassen Assenov; Doreen Heckmann; Nikos Sidiropoulos; Sebastian M Waszak; Daniel Hübschmann; Alfonso Urbanucci; Etsehiwot G Girma; Vladimir Kuryshev; Leszek J Klimczak; Natalie Saini; Adrian M Stütz; Dieter Weichenhan; Lisa-Marie Böttcher; Reka Toth; Josephine D Hendriksen; Christina Koop; Pavlo Lutsik; Sören Matzk; Hans-Jörg Warnatz; Vyacheslav Amstislavskiy; Clarissa Feuerstein; Benjamin Raeder; Olga Bogatyrova; Eva-Maria Schmitz; Claudia Hube-Magg; Martina Kluth; Hartwig Huland; Markus Graefen; Chris Lawerenz; Gervaise H Henry; Takafumi N Yamaguchi; Alicia Malewska; Jan Meiners; Daniela Schilling; Eva Reisinger; Roland Eils; Matthias Schlesner; Douglas W Strand; Robert G Bristow; Paul C Boutros; Christof von Kalle; Dmitry Gordenin; Holger Sültmann; Benedikt Brors; Guido Sauter; Christoph Plass; Marie-Laure Yaspo; Jan O Korbel; Thorsten Schlomm; Joachim Weischenfeldt
Journal:  Cancer Cell       Date:  2018-12-10       Impact factor: 31.743

2.  Commentary on "Integrative clinical genomics of advanced prostate cancer". Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.Cell. 21 May 2015;161(5):1215-1228.

Authors:  Stephen J Freedland; William J Aronson
Journal:  Urol Oncol       Date:  2017-06-13       Impact factor: 3.498

3.  Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells.

Authors:  Josep Domingo-Domenech; Samuel J Vidal; Veronica Rodriguez-Bravo; Mireia Castillo-Martin; S Aidan Quinn; Ruth Rodriguez-Barrueco; Dennis M Bonal; Elizabeth Charytonowicz; Nataliya Gladoun; Janis de la Iglesia-Vicente; Daniel P Petrylak; Mitchell C Benson; Jose M Silva; Carlos Cordon-Cardo
Journal:  Cancer Cell       Date:  2012-09-11       Impact factor: 31.743

4.  A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.

Authors:  E D Crawford; M A Eisenberger; D G McLeod; J T Spaulding; R Benson; F A Dorr; B A Blumenstein; M A Davis; P J Goodman
Journal:  N Engl J Med       Date:  1989-08-17       Impact factor: 91.245

5.  Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

Authors:  Nicholas D James; Johann S de Bono; Melissa R Spears; Noel W Clarke; Malcolm D Mason; David P Dearnaley; Alastair W S Ritchie; Claire L Amos; Clare Gilson; Rob J Jones; David Matheson; Robin Millman; Gerhardt Attard; Simon Chowdhury; William R Cross; Silke Gillessen; Christopher C Parker; J Martin Russell; Dominik R Berthold; Chris Brawley; Fawzi Adab; San Aung; Alison J Birtle; Jo Bowen; Susannah Brock; Prabir Chakraborti; Catherine Ferguson; Joanna Gale; Emma Gray; Mohan Hingorani; Peter J Hoskin; Jason F Lester; Zafar I Malik; Fiona McKinna; Neil McPhail; Julian Money-Kyrle; Joe O'Sullivan; Omi Parikh; Andrew Protheroe; Angus Robinson; Narayanan N Srihari; Carys Thomas; John Wagstaff; James Wylie; Anjali Zarkar; Mahesh K B Parmar; Matthew R Sydes
Journal:  N Engl J Med       Date:  2017-06-03       Impact factor: 91.245

6.  OncoKB: A Precision Oncology Knowledge Base.

Authors:  Debyani Chakravarty; Jianjiong Gao; Sarah M Phillips; Ritika Kundra; Hongxin Zhang; Jiaojiao Wang; Julia E Rudolph; Rona Yaeger; Tara Soumerai; Moriah H Nissan; Matthew T Chang; Sarat Chandarlapaty; Tiffany A Traina; Paul K Paik; Alan L Ho; Feras M Hantash; Andrew Grupe; Shrujal S Baxi; Margaret K Callahan; Alexandra Snyder; Ping Chi; Daniel Danila; Mrinal Gounder; James J Harding; Matthew D Hellmann; Gopa Iyer; Yelena Janjigian; Thomas Kaley; Douglas A Levine; Maeve Lowery; Antonio Omuro; Michael A Postow; Dana Rathkopf; Alexander N Shoushtari; Neerav Shukla; Martin Voss; Ederlinda Paraiso; Ahmet Zehir; Michael F Berger; Barry S Taylor; Leonard B Saltz; Gregory J Riely; Marc Ladanyi; David M Hyman; José Baselga; Paul Sabbatini; David B Solit; Nikolaus Schultz
Journal:  JCO Precis Oncol       Date:  2017-05-16

7.  Oncogenic Signaling Pathways in The Cancer Genome Atlas.

Authors:  Francisco Sanchez-Vega; Marco Mina; Joshua Armenia; Walid K Chatila; Augustin Luna; Konnor C La; Sofia Dimitriadoy; David L Liu; Havish S Kantheti; Sadegh Saghafinia; Debyani Chakravarty; Foysal Daian; Qingsong Gao; Matthew H Bailey; Wen-Wei Liang; Steven M Foltz; Ilya Shmulevich; Li Ding; Zachary Heins; Angelica Ochoa; Benjamin Gross; Jianjiong Gao; Hongxin Zhang; Ritika Kundra; Cyriac Kandoth; Istemi Bahceci; Leonard Dervishi; Ugur Dogrusoz; Wanding Zhou; Hui Shen; Peter W Laird; Gregory P Way; Casey S Greene; Han Liang; Yonghong Xiao; Chen Wang; Antonio Iavarone; Alice H Berger; Trever G Bivona; Alexander J Lazar; Gary D Hammer; Thomas Giordano; Lawrence N Kwong; Grant McArthur; Chenfei Huang; Aaron D Tward; Mitchell J Frederick; Frank McCormick; Matthew Meyerson; Eliezer M Van Allen; Andrew D Cherniack; Giovanni Ciriello; Chris Sander; Nikolaus Schultz
Journal:  Cell       Date:  2018-04-05       Impact factor: 41.582

8.  The mutational landscape of lethal castration-resistant prostate cancer.

Authors:  Catherine S Grasso; Yi-Mi Wu; Dan R Robinson; Xuhong Cao; Saravana M Dhanasekaran; Amjad P Khan; Michael J Quist; Xiaojun Jing; Robert J Lonigro; J Chad Brenner; Irfan A Asangani; Bushra Ateeq; Sang Y Chun; Javed Siddiqui; Lee Sam; Matt Anstett; Rohit Mehra; John R Prensner; Nallasivam Palanisamy; Gregory A Ryslik; Fabio Vandin; Benjamin J Raphael; Lakshmi P Kunju; Daniel R Rhodes; Kenneth J Pienta; Arul M Chinnaiyan; Scott A Tomlins
Journal:  Nature       Date:  2012-07-12       Impact factor: 49.962

9.  Genomics of lethal prostate cancer at diagnosis and castration resistance.

Authors:  Joaquin Mateo; George Seed; Claudia Bertan; Pasquale Rescigno; David Dolling; Ines Figueiredo; Susana Miranda; Daniel Nava Rodrigues; Bora Gurel; Matthew Clarke; Mark Atkin; Rob Chandler; Carlo Messina; Semini Sumanasuriya; Diletta Bianchini; Maialen Barrero; Antonella Petermolo; Zafeiris Zafeiriou; Mariane Fontes; Raquel Perez-Lopez; Nina Tunariu; Ben Fulton; Robert Jones; Ursula McGovern; Christy Ralph; Mohini Varughese; Omi Parikh; Suneil Jain; Tony Elliott; Shahneen Sandhu; Nuria Porta; Emma Hall; Wei Yuan; Suzanne Carreira; Johann S de Bono
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

10.  Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.

Authors:  Theo A Knijnenburg; Linghua Wang; Michael T Zimmermann; Nyasha Chambwe; Galen F Gao; Andrew D Cherniack; Huihui Fan; Hui Shen; Gregory P Way; Casey S Greene; Yuexin Liu; Rehan Akbani; Bin Feng; Lawrence A Donehower; Chase Miller; Yang Shen; Mostafa Karimi; Haoran Chen; Pora Kim; Peilin Jia; Eve Shinbrot; Shaojun Zhang; Jianfang Liu; Hai Hu; Matthew H Bailey; Christina Yau; Denise Wolf; Zhongming Zhao; John N Weinstein; Lei Li; Li Ding; Gordon B Mills; Peter W Laird; David A Wheeler; Ilya Shmulevich; Raymond J Monnat; Yonghong Xiao; Chen Wang
Journal:  Cell Rep       Date:  2018-04-03       Impact factor: 9.423
View more
  36 in total

1.  Olaparib for DNA repair-deficient prostate cancer - one for all, or all for one?

Authors:  Emmanuel S Antonarakis
Journal:  Nat Rev Clin Oncol       Date:  2020-08       Impact factor: 66.675

2.  Clinical and genomic features of SPOP-mutant prostate cancer.

Authors:  Mari Nakazawa; Mike Fang; Catherine H Marshall; Tamara L Lotan; Pedro Isaacsson Velho; Emmanuel S Antonarakis
Journal:  Prostate       Date:  2021-11-15       Impact factor: 4.104

Review 3.  Genomic biomarkers to guide precision radiotherapy in prostate cancer.

Authors:  Philip Sutera; Matthew P Deek; Kim Van der Eecken; Alexander W Wyatt; Amar U Kishan; Jason K Molitoris; Matthew J Ferris; M Minhaj Siddiqui; Zaker Rana; Mark V Mishra; Young Kwok; Elai Davicioni; Daniel E Spratt; Piet Ost; Felix Y Feng; Phuoc T Tran
Journal:  Prostate       Date:  2022-08       Impact factor: 4.012

4.  Identifying Phased Mutations and Complex Rearrangements in Human Prostate Cancer Cell Lines through Linked-Read Whole-Genome Sequencing.

Authors:  Minh-Tam Pham; Anuj Gupta; Harshath Gupta; Ajay Vaghasia; Alyza Skaist; McKinzie A Garrison; Jonathan B Coulter; Michael C Haffner; S Lilly Zheng; Jianfeng Xu; Christina DeStefano Shields; William B Isaacs; Sarah J Wheelan; William G Nelson; Srinivasan Yegnasubramanian
Journal:  Mol Cancer Res       Date:  2022-07-06       Impact factor: 6.333

5.  Population-Based Study of Docetaxel or Abiraterone Effectiveness and Predictive Markers of Progression Free Survival in Metastatic Castration-Sensitive Prostate Cancer.

Authors:  Juan Briones; Maira Khan; Amanjot K Sidhu; Liying Zhang; Martin Smoragiewicz; Urban Emmenegger
Journal:  Front Oncol       Date:  2021-05-07       Impact factor: 6.244

6.  TP53 alterations of hormone-naïve prostate cancer in the Chinese population.

Authors:  Zhengfang Liu; Hu Guo; Yaofeng Zhu; Yangyang Xia; Jianfeng Cui; Kai Shi; Yidong Fan; Benkang Shi; Shouzhen Chen
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-11-19       Impact factor: 5.554

7.  Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell-Level PI3K Pathway Activation.

Authors:  Konrad H Stopsack; Ying Huang; Svitlana Tyekucheva; Travis A Gerke; Clyde Bango; Habiba Elfandy; Michaela Bowden; Kathryn L Penney; Thomas M Roberts; Giovanni Parmigiani; Philip W Kantoff; Lorelei A Mucci; Massimo Loda
Journal:  Clin Cancer Res       Date:  2020-09-10       Impact factor: 12.531

8.  Accelerating precision medicine in metastatic prostate cancer.

Authors:  Joaquin Mateo; Rana McKay; Wassim Abida; Rahul Aggarwal; Joshi Alumkal; Ajjai Alva; Felix Feng; Xin Gao; Julie Graff; Maha Hussain; Fatima Karzai; Bruce Montgomery; William Oh; Vaibhav Patel; Dana Rathkopf; Matthew Rettig; Nikolaus Schultz; Matthew Smith; David Solit; Cora Sternberg; Eliezer Van Allen; David VanderWeele; Jake Vinson; Howard R Soule; Arul Chinnaiyan; Eric Small; Jonathan W Simons; William Dahut; Andrea K Miyahira; Himisha Beltran
Journal:  Nat Cancer       Date:  2020-11-17

9.  A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer.

Authors:  Phillip L Palmbos; Stephanie Daignault-Newton; Scott A Tomlins; Neeraj Agarwal; Przemyslaw Twardowski; Alicia K Morgans; Wm Kevin Kelly; Vivek K Arora; Emmanuel S Antonarakis; Javed Siddiqui; Jon A Jacobson; Matthew S Davenport; Dan R Robinson; Arul M Chinnaiyan; Karen E Knudsen; Maha Hussain
Journal:  Clin Cancer Res       Date:  2021-03-16       Impact factor: 12.531

Review 10.  Local Therapies in Oligometastatic and Oligoprogressive Prostate Cancer.

Authors:  Matthew P Deek; Ryan M Phillips; Phuoc T Tran
Journal:  Semin Radiat Oncol       Date:  2021-07       Impact factor: 5.421
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.